Small molecule inhibitors targeting the EGFR/Eps8 complex in NSCLC and breast cancer models have shown promising results, supporting Eps8 as a potential therapeutic target in cancer (Li et al, 2019). This evidence concerns the gene EPS8 and breast cancer.